Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AT19
- Development stage
- Unknown
- Lead developer
- Ucello Biotechnology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
AT19 is a universal chimeric antigen receptor T cell (CAR-T) therapy developed by Ucello Therapeutics. It is designed to target CD19, a protein expressed on the surface of B cells. The drug functions as a CD19 inhibitor and is intended for the treatment of hematological malignancies that express CD19, such as B-cell lymphoma and CD19-positive acute lymphoblastic leukemia. As a universal CAR-T product, it aims to provide an off-the-shelf cellular immunotherapy option for patients with relapsed or refractory blood cancers[1].
- Other names
- AT19AT-19AT 19AT-I9AT-I-9AT-I 9ATI9ATI-9ATI 9
02
Targets
Beyond the preview
Go deeper on AT19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AT19.